Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
AGOURA HILLS, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer and other indications with unmet medical needs, announced today that IBM has granted access to its IBM Clinical Development (ICD) platform free of charge for the clinical trial evaluating the potential of Mateon’s lead drug candidate OT-101 in COVID-19 patients. The award was made following IBM’s review of the program and is designed to help accelerate the upcoming phase II COVID-19 clinical trial. IBM is supporting COVID-19 clinical research through an initiative to help support trial sponsors with promising therapeutic and vaccine candidates.
“We are working tirelessly to ensure that OT-101 proves to be safe and efficacious for patients with COVID-19. It is clear that we are going to need the most innovative and nimble partners as we apply the latest technologies and endeavor to develop meaningful treatments for COVID-19 patients,” said Vuong Trieu, CEO, Mateon Therapeutics. “We believe that the IBM Clinical Development solution can be extremely valuable in creating the efficiencies needed to accelerate the clinical trial process.”
The ICD platform offering from IBM Watson Health is a cloud-based, end-to-end clinical development system used by leading CROs and designed to reduce the time and cost of clinical trials. ICD solutions include electronic patient reported outcomes (ePRO), data integration, reporting and analytics, quality and compliance, medical coding, endpoint analysis, randomization, and clinical trial supply management. Remote monitoring of patients is possible through the system’s ePRO technology, which could become crucial in rapidly completing clinical studies as new “hot-spots” of infection arise across the globe.
“The COVID-19 pandemic is an unprecedented global public health crisis and there is an increasing sense of urgency to develop safe and effective treatments as infection rates continue to escalate at an alarming rate,” said Mary Varghese Presti, Vice President, Life Sciences, IBM Watson Health. “We are committed to leveraging our ICD solution to help accelerate the timelines for COVID-19 clinical trials and are enabling access to the platform, free of charge, for relevant trial sponsors. We are inspired by Mateon’s commitment, a well as all of the other leaders in the life sciences community, as they apply their expertise and ingenuity to help millions of patients worldwide. IBM is proud to play a meaningful role in this ambitious effort.”
About Mateon Therapeutics
About Mateon’s Lead Product Candidate, OT-101
Mateon's Cautionary Note on Forward-Looking Statements